

Samuel T Workenhe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2165373/publications.pdf>

Version: 2024-02-01

19
papers

1,631
citations

516710

16
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

3000
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Tumor-intrinsic determinants of immunogenic cell death modalities. <i>OncolImmunology</i> , 2021, 10, 1893466. | 4.6 | 30 |
| 2 | Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. <i>Communications Biology</i> , 2021, 4, 859. | 4.4 | 13 |
| 3 | Genetic modification of oncolytic viruses to enhance antitumor immunity. <i>Methods in Enzymology</i> , 2020, 635, 231-250. | 1.0 | 2 |
| 4 | Cytokines in oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 4-27. | 7.2 | 33 |
| 5 | Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. , 2020, 8, e000981. | | 15 |
| 6 | De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. <i>Communications Biology</i> , 2020, 3, 645. | 4.4 | 30 |
| 7 | Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. <i>Journal of Immunology</i> , 2018, 200, 450-458. | 0.8 | 78 |
| 8 | HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. <i>Cell Reports</i> , 2018, 24, 642-654. | 6.4 | 19 |
| 9 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>OncolImmunology</i> , 2018, 7, e1503032. | 4.6 | 67 |
| 10 | The role of oncolytic virus immunotherapies to subvert cancer immune evasion. <i>Future Oncology</i> , 2015, 11, 675-689. | 2.4 | 18 |
| 11 | Consensus guidelines for the detection of immunogenic cell death. <i>OncolImmunology</i> , 2014, 3, e955691. | 4.6 | 686 |
| 12 | Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. <i>Molecular Therapy</i> , 2014, 22, 123-131. | 8.2 | 93 |
| 13 | Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies. <i>Molecular Therapy</i> , 2014, 22, 251-256. | 8.2 | 160 |
| 14 | Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. <i>OncolImmunology</i> , 2013, 2, e27138. | 4.6 | 22 |
| 15 | Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. <i>Cancer Immunology Research</i> , 2013, 1, 309-319. | 3.4 | 62 |
| 16 | Countermeasures against viral diseases of farmed fish. <i>Antiviral Research</i> , 2012, 95, 257-281. | 4.1 | 92 |
| 17 | The fight between the teleost fish immune response and aquatic viruses. <i>Molecular Immunology</i> , 2010, 47, 2525-2536. | 2.2 | 126 |
| 18 | Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (<i>Salmo salar</i>) macrophage/dendritic-like cell line TO, assessed using genomic techniques. <i>Molecular Immunology</i> , 2009, 46, 2955-2974. | 2.2 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Absolute quantitation of infectious salmon anaemia virus using different real-time reverse transcription PCR chemistries. Journal of Virological Methods, 2008, 154, 128-134. | 2.1 | 22 |